The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Summary

The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer, and whether the side effects of the combined hormonal therapy are different from the side effects of letrozole.

Timeline

Start

2004-12

Primary completion

—

Completion

2006-08

Outcome

Outcome not reported

Stopped: “Identical study Biomed 777-CLP-029 did not meet superiority endpoint”

Drugs

Indications